Oxidative stress markers in young hemodialysis patients - A pilot study

Clinical Nephrology

Volumn 70, Issue 2, 2008, Pages 135-143

  Nissel, R ^a   Faraj, S ^a   Sommer, K ^a   Henning, L ^a   Van der Giet, M ^a   Querfeld, Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arteriosclerosis; Cardiovascular disease; Dialysis; Oxidative stress; Young age

Indexed keywords

GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COMMON CAROTID ARTERY; COMORBIDITY; CONTROLLED STUDY; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; LIPOPROTEIN BLOOD LEVEL; MALE; OXIDATIVE STRESS; PEAK EXPIRATORY FLOW; PILOT STUDY; PROGNOSIS; RISK ASSESSMENT; TREATMENT DURATION; VASCULAR DISEASE; VASCULARIZATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

EID: 48749117171     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70135     Document Type: Article

References (41)

1. Afzal M, Afzal A, Jones A, Armstrong D. A rapid method for the quantification of GSH and GSSG in biological samples. In: Armstrong D (ed). Oxidative stress biomarkers and antioxidant protocols. Totowa, NJ: Humana Press; 2002. p. 117-122.
2. Ahotupa M, Marniemi J, Lehtimaki T, Talvinen K, Raitakari OT, Vasankari T, Viikari J, Luoma J, Yla-Herttuala S. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem. 1998; 31: 257-261.
3. Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. Oxidative stress markers in pre-uremic patients. Clin Nephrol. 2001a; 56: 308-314.
4. Annuk M, Zilmer M, Lind L, Linde T, Fellstrom B. Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001b; 12: 2747-2752.
5. Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis. Kidney Int. 1999; 55: 1536-1542.
6. Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other nontraditional cardiac risk factors. J Am Soc Nephrol. 1997; 8: 475-486.
7. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol. 2001; 12: 2458-2464.
8. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation 1995; 91: 2488-2496.
9. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000; 356: 1213-1218.
10. Bolton CH, Downs LG, Victory JG, Dwight JF, Tomson CR, Mackness MI, Pinkney JH. Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2001; 16: 1189-1197.
11. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease - impact of calcium and vitamin D therapy. Nephrol Dial Transplant. 2006; 21: 1906-1914.
12. Capuano A, Sepe V, Cianfrone P, Castellano T, Andreucci VE. Cardiovascular impairment, dialysis strategy and tolerance in elderly and young patients on maintenance haemodialysis. Nephrol Dial Transplant. 1990; 5: 1023-1030.
13. Ceballos-Picot I, Trivier JM, Nicole A, Sinet PM, Thevenin M. Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes. Clin Chem. 1992; 38: 66-70.
14. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, Nguyen AT, Thevenin M, Jaudon MC, Zingraff J, Verger C, Jungers P, Descamps-Latscha B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic Biol Med. 1996; 21: 845-853.
15. Demacker PN, Hessels M, Toenhake-Dijkstra H, Baadenhuijsen H. Precipitation methods for high-density lipoprotein cholesterol measurement compared, and final evaluation under routine operating conditions of a method with a low sample-to-reagent ratio. Clin Chem. 1997; 43: 663-668.
16. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-S119.
17. Galle J, Hansen-Hagge T, Wanner C, Seibold S. Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis. 2006; 185: 219-226.
18. Gordon CA, Himmelfarb J. Antioxidant therapy in uremia: evidence-based medicine? Semin Dial. 2004; 17: 327-332.
19. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15: 1014-1021.
20. Haydar AA, Hujairi NM, Covic AA, Pereira D, Rubens M, Goldsmith DJ. Coronary artery calcification is related to coronary atherosclerosis in chronic renal disease patients: a study comparing EBCT-generated coronary artery calcium scores and coronary angiography. Nephrol Dial Transplant. 2004; 19: 2307-2312.
21. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Lesaffre E, Vanrenterghem Y, Collen D. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure. Thromb Haemost. 1996; 76: 663-669.
22. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int. 2003; 64: 1472-1479.
23. Kaysen GA, Eiserich JP. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction. J Am Soc Nephrol. 2004; 15: 538-548.
24. Kohlmeier M. Simple method for preparing and quantifying very-low density lipoprotein. Clin Chem. 1984; 30: 295-297.
25. Kohlmeier M. Direct enzymic measurement of glycerides in serum and in lipoprotein fractions. Clin Chem. 1986; 32: 63-66.
26. London GM, Guerin AP, Marchais SJ, Metivier F, Panier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18: 1731-1740.
27. Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: markers and management. J Nephrol. 2002; 15: 336-341.
28. Nguyen-Khoa T, Massy ZA, De Bandt JP, Kebede M, Salama L, Lambrey G, Witko-Sarsat V, Drueke TB, Lacour B, Thevenin M. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant. 2001; 16: 335-340.
29. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967; 70: 158-169.
30. Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA. Uremic malnutrition is a predictor of death independent of inflammatory status. Kidney Int. 2004; 66: 2054-2060.
31. Rifai N, King ME. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem. 1986; 32: 957-961.
32. Schumaker VN, Puppione DL. Sequential flotation ultracentrifugation. Methods Enzymol. 1986; 128: 155-170.
33. Steinberg D, Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation. 1997; 95: 1062-1071.
34. Sumner D. Volume plethysmography in vascular disease: an overview. In: Berstein E (ed). Noninvasive diagnostic techniques in vascular disease. St Louis, CV; 1985. p. 97-118.
35. Takenaka T, Takahashi K, Kobayashi T, Oshima E, Iwasaki S, Suzuki H. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol. 2002; 58: 33-37.
36. Takenaka T, Itaya Y, Suzuki H. Young hemodialysis patients are exposed to hyperhomocysteinemia. J Ren Nutr. 2005; 15: 435-440.
37. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation. 2003; 107: 992-995.
38. Vaziri ND. Oxidative stress in uremia: nature, mechanisms and potential consequences. Semin Nephrol. 2004; 24: 469-473.
39. Woolliams JA, Wiener G, Anderson PH, McMurray CH. Variation in the activities of glutathione peroxidase and superoxide dismutase and in the concentration of copper in the blood in various breed crosses of sheep. Res Vet Sci. 1983; 34: 253-256.
40. Yao Q, Pecoits-Filho R, Lindholm B, Stenvinkel P. Traditional and nontraditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease. Scand J Urol Nephrol. 2004; 38: 405-416.
41. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.